The Kechuang 50 index opened slightly higher in the morning on January 18. After a short adjustment at the beginning of the index, it rebounded sharply. It once rose about 1.8% in the morning. After that, it fell back and rose about 0.5% at the noon closing. It was sorted out narrowly in the afternoon and finally closed up slightly. At the close, the Kechuang 50 index rose 0.30% and the index amplitude was 2.55%.
From the disk point of view, the rise and fall of Kechuang 50 index shows that the capital contribution is still different from the future market. On the 18th, individual stocks on the science and Innovation Board rose less and fell more. Some stocks that disclosed the announcement of performance pre increase opened higher in early trading, but they mostly fell after rising.
In terms of subdivided areas, virus detection stocks fell sharply across the board, dragging down the general adjustment of medical and health care stocks; Software services rose higher, while integrated circuit stocks rose slightly.
Maiwei biology was listed on the science and Innovation Board of Shanghai Stock Exchange on January 18, and the number of listed enterprises on the science and Innovation Board increased to 383.
Maiwei biological securities code is 688062, and the issue price is 34.80 yuan / share. Maiwei bio is an innovative biopharmaceutical enterprise. Its main business is the R & D, production and sales of therapeutic biological products, specifically antibody drugs including human therapeutic monoclonal antibodies, bispecific / bifunctional antibodies and ADC drugs, as well as long-acting or specially modified cytokine recombinant protein drugs. Maiwei biology has three echelons covering the fields of autoimmunity, tumor, metabolism, ophthalmology, infection and other diseases, with a total of 16 varieties under research. As of the closing, Maiwei biological fell 29.60% compared with the issue price, the turnover rate was 53.61%, and the turnover was about 1.221 billion yuan.
According to the statistics of Xinhua Finance and economics, as of the closing, excluding Maiwei biology on the first day of listing, the average decline of the remaining 382 stocks on the science and Innovation Board was 1.66%, the average turnover rate was 4.35%, and the total turnover was 61.288 billion yuan, with an average amplitude of 5.21%.
In terms of individual stock performance, Longyan Zhuoyue New Energy Co.Ltd(688196) rose 11.31%, ranking the first; Excluding Maiwei biology on the first day of listing, Hangzhou Alltest Biotech Co.Ltd(688606) fell by 20.00%, ranking the first.
In terms of turnover, Zhejiang Orient Gene Biotech Co.Ltd(688298) turnover was 2.788 billion yuan, ranking first; Shanghai Ceo Environmental Protection Technology Co.Ltd(688335) the turnover was 5.147 million yuan, ranking last.
In terms of turnover rate, regardless of Maiwei biology on the first day of listing, Hangzhou Biotest Biotech Co.Ltd(688767) turnover rate was 36.07%, ranking first; The turnover rate of No. 9 company was 0.25%, ranking last.
